Eintrag weiter verarbeiten
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , |
| In: | Clinical Cancer Research, 18, 2012, 8, S. 2130-2132 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
LeBlanc, Michael Tangen, Catherine LeBlanc, Michael Tangen, Catherine |
|---|---|
| author |
LeBlanc, Michael Tangen, Catherine |
| spellingShingle |
LeBlanc, Michael Tangen, Catherine Clinical Cancer Research Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Cancer Research Oncology |
| author_sort |
leblanc, michael |
| spelling |
LeBlanc, Michael Tangen, Catherine 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-12-0454 <jats:title>Abstract</jats:title> <jats:p>Selecting the phase II design and endpoint to achieve the best possible chance of success for a confirmatory phase III study in a particular disease and treatment setting is challenging but critical. Simulating from existing clinical trial data sets and from mathematical models can be useful tools for evaluating statistical properties. Clin Cancer Res; 18(8); 2130–2. ©2012 AACR.</jats:p> Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-12-0454 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA0NTQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA0NTQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2012 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
leblanc2012choosingphaseiiendpointsanddesignsevaluatingthepossibilities |
| publishDateSort |
2012 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_unstemmed |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_full |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_fullStr |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_full_unstemmed |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_short |
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_sort |
choosing phase ii endpoints and designs: evaluating the possibilities |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-12-0454 |
| publishDate |
2012 |
| physical |
2130-2132 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Selecting the phase II design and endpoint to achieve the best possible chance of success for a confirmatory phase III study in a particular disease and treatment setting is challenging but critical. Simulating from existing clinical trial data sets and from mathematical models can be useful tools for evaluating statistical properties. Clin Cancer Res; 18(8); 2130–2. ©2012 AACR.</jats:p> |
| container_issue |
8 |
| container_start_page |
2130 |
| container_title |
Clinical Cancer Research |
| container_volume |
18 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348330765844485 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:09:11.685Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Choosing+Phase+II+Endpoints+and+Designs%3A+Evaluating+the+Possibilities&rft.date=2012-04-15&genre=article&issn=1557-3265&volume=18&issue=8&spage=2130&epage=2132&pages=2130-2132&jtitle=Clinical+Cancer+Research&atitle=Choosing+Phase+II+Endpoints+and+Designs%3A+Evaluating+the+Possibilities&aulast=Tangen&aufirst=Catherine&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-12-0454&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348330765844485 |
| author | LeBlanc, Michael, Tangen, Catherine |
| author_facet | LeBlanc, Michael, Tangen, Catherine, LeBlanc, Michael, Tangen, Catherine |
| author_sort | leblanc, michael |
| container_issue | 8 |
| container_start_page | 2130 |
| container_title | Clinical Cancer Research |
| container_volume | 18 |
| description | <jats:title>Abstract</jats:title> <jats:p>Selecting the phase II design and endpoint to achieve the best possible chance of success for a confirmatory phase III study in a particular disease and treatment setting is challenging but critical. Simulating from existing clinical trial data sets and from mathematical models can be useful tools for evaluating statistical properties. Clin Cancer Res; 18(8); 2130–2. ©2012 AACR.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-12-0454 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA0NTQ |
| imprint | American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2012 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T18:09:11.685Z |
| match_str | leblanc2012choosingphaseiiendpointsanddesignsevaluatingthepossibilities |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 2130-2132 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | LeBlanc, Michael Tangen, Catherine 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-12-0454 <jats:title>Abstract</jats:title> <jats:p>Selecting the phase II design and endpoint to achieve the best possible chance of success for a confirmatory phase III study in a particular disease and treatment setting is challenging but critical. Simulating from existing clinical trial data sets and from mathematical models can be useful tools for evaluating statistical properties. Clin Cancer Res; 18(8); 2130–2. ©2012 AACR.</jats:p> Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Clinical Cancer Research |
| spellingShingle | LeBlanc, Michael, Tangen, Catherine, Clinical Cancer Research, Choosing Phase II Endpoints and Designs: Evaluating the Possibilities, Cancer Research, Oncology |
| title | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_full | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_fullStr | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_full_unstemmed | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_short | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| title_sort | choosing phase ii endpoints and designs: evaluating the possibilities |
| title_unstemmed | Choosing Phase II Endpoints and Designs: Evaluating the Possibilities |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-12-0454 |